Evidence map›Paper›PMID 42818885›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Effects of sex, treatment resistance, and antidepressant treatment on monoamine oxidase B total distribution volume.

Emily Jy Kuik, Catalina Baena-Tan, Sho Moriguchi, Joeffre Braga, Laura Miler, Pablo Rusjan, Michael Bagby, M Ishrat Husain, Neil Vasdev, Toshifumi Tomoda and 3 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Emily Jy KuikBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Catalina Baena-TanBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Sho MoriguchiDepartment of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.ORCID 0000-0001-7536-9708
Joeffre BragaBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Laura MilerBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Pablo RusjanDouglas Research Centre and Department of Psychiatry, McGill University, Montreal, QC, Canada.ORCID 0000-0003-0075-2918
Michael BagbyDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
M Ishrat HusainDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5771-5750
Neil VasdevBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.ORCID 0000-0002-2087-5125
Toshifumi TomodaDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-3587-0914
Mounira BanasrDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Stefan KloiberDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6838-4114
Jeffrey H MeyerBrain Health Imaging Centre and Azrieli Centre for Neuro-Radiochemistry, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.ORCID 0000-0003-4684-5052

Funding

Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer [11C]SL2511.88R01MH115014 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MEYER, JEFFREY H · 2018 to 2022
$1.2M
NIMH NIH HHS R01 MH115014
6 · The paper itself

Abstract

Monoamine oxidase B (MAO-B) is a high-density protein located mainly in astrocytes that influences mitochondrial function and transition to astrogliosis. MAO-B produces hydrogen peroxide while metabolizing non-serotonergic monoamines. Elevated MAO-B level is implicated in the pathophysiology of several common neuropsychiatric diseases. The aims are to examine the effect of treatment resistant major depressive episodes, sex, and antidepressant treatment on MAO-B total distribution volume ([

Identifiers

PMID42818885
PMCPMC13622770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.